Screening, Optimization and Production of Uricase from a Novel Actinomycete Isolate A85

Background: Uricase is used to diagnose the presence of uric acid in biological fluids as well as to cure gout. Uric acid concentrations in -biological fluids are elevated by several medical disorders. Chronic renal disorders, certain organic acidemias and gout are all possible outcomes of such circumstances. Objectives: The current endeavor is primarily focused on isolating new, promising uricase-producing isolate, carrying out molecular identification and optimizing the enzyme’s production. Materials and Methods: Based on the screening of the isolates for the synthesis of uricase, eight existed isolates in the laboratory were examined for their uricase activity and isolate A85 which showed the maximum zone of clearance was chosen as the promising strain. Based on routine biochemical and physical characterization, it was determined to be a variant of Streptomyces enissocaesilis after molecular analysis using the 16S rRNA sequence revealed a 99.73% similarity to Streptomyces enissocaesilis. Results: Using the One Factor at a Time method in a submerged fermentation process under ideal conditions, Streptomyces enissocaesilis produced uricase in concentrations ranging from 0.06 to 3.81 U/mL. The uricase production was increased to 7.53 U/mL from 3.33 U/mL with the optimized medium, which has the following ingredients: pH 9.0±0.2, sucrose (2%), peptone (0.5%), uric acid (0.3%), Na2HPO4 (0.1%), NaCl (0.05%), MgSO4.7H2O (0.05%) and CaCl2 (0.05%). The isolate A85 nucleotide sequence (16S rRNA) was uploaded in Gene Bank (NCBI) with the Accession number: OR964862.1. Conclusion: The investigation showed that the unique pre-existed marine isolate A85 was a potential uricase producer and was identified as a variant of Streptomyces enissocaesilis.